IL-23 targeting double-bridged peptides (EPFL)

N/A

Report date: 2025/01/26 17:43:14

Base Information

Drug NameIL-23 targeting double-bridged peptides (EPFL)
Drug Alias NameIL-23 targeting enzyme-resistant peptides (EPFL)
ClassificationBiologics > Protein drugs > Recombinant polypeptide
Mechanisms of ActionInterleukin 23 Receptor modulators
TargetsInterleukin 23 Receptor
Therapy Area/IndicationsCrohn DiseaseColitis, Ulcerative
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritorySwitzerland
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesEcole Polytechnique Federale De Lausanne
China Registration ClassN/A

Develop Information

Active CompaniesEcole Polytechnique Federale De Lausanne
Inactive CompaniesN/A
Active IndicationsCrohn DiseaseColitis, Ulcerative
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A